BUFFALO, N.Y., May 03, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the
discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, will release
first quarter 2018 earnings results on May 14, 2018. The Company will host a conference call and audio webcast on Monday, May 14,
2018 at 9:00 a.m. Eastern Time.
To participate in the call, dial (855) 227-0567 (domestic) or (612) 979-9912 (international) fifteen minutes before the
conference call begins and reference the conference passcode 9093904. A replay will be available approximately one hour after the
recording through Monday, May 21, 2018 and can be accessed by dialing (855) 859-2056. The live conference call and replay can also
be accessed via audio webcast at the Investor Relations section of the Company’s website, located at www.athenex.com. An
archive will be available at this website until June 14, 2018.
About Athenex, Inc.
Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the
discovery and development of next generation drugs for the treatment of cancer. Athenex is organized around three
platforms, including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. Athenex’s Oncology
Innovation Platform generates clinical candidates through an extensive understanding of kinases, including novel binding sites and
human absorption biology, as well as through the application of Athenex’s proprietary research and selection processes in the lab.
The Company’s current clinical pipeline is derived from two different platform technologies Athenex calls Orascovery and
Src Kinase Inhibition. The Orascovery platform is based on the novel oral P-glycoprotein pump inhibitor molecule HM30181A, through
which Athenex is able to facilitate oral absorption of traditional cytotoxics, which Athenex believes may offer
improved patient tolerability and efficacy as compared to IV administration of the same cytotoxics. The Orascovery platform was
developed by Hanmi Pharmaceuticals and licensed exclusively to Athenex for all major worldwide territories
except Korea, which is retained by Hanmi. The Src Kinase Inhibition platform refers to novel small molecule compounds that
have multiple mechanisms of action, including the inhibition of the activity of Src Kinase and the inhibition of tubulin
polymerization during cell division. Athenex believes the combination of these mechanisms of action provides a broader range
of anti-cancer activity as compared to either mechanism of action alone. Athenex’s employees worldwide are dedicated to improving
the lives of cancer patients by creating more active and tolerable treatments. Athenex has offices
in Buffalo and Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago, Illinois; Hong
Kong; Taipei, Taiwan and multiple locations in Chongqing, China.
CONTACT:
Jim Polson
Tel: +1-716-427-2952
Athenex, Inc.
